Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 225,385,820 papers from all fields of science
Search
Sign In
Create Free Account
eliglustat
Known as:
N-((1R,2R)-2-(2,3-Dihydro-1,4-benzodioxin-6-yl)-2-hydroxy-1-(pyrrolidin-1-ylmethyl)ethyl)octanamide
, N-[(1R,2R)-1-(2,3-Dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-(1-pyrrolidinyl)-2-propanyl]octanamide
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
6 relations
Broader (2)
Enzyme Inhibitors
Pyrrolidines
Narrower (2)
Genz-112638
eliglustat tartrate
eliglustat 84 MG Oral Capsule
eliglustat 84 MG Oral Capsule [Cerdelga]
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Effect of eliglustat on the pharmacokinetics of digoxin, metoprolol, and oral contraceptives and absorption of eliglustat when coadministered with acid-reducing agents.
N. Thibault
,
J. Ibrahim
,
+5 authors
S. Turpault
Molecular Genetics and Metabolism
2020
Corpus ID: 211044789
2018
2018
Process for preparation of eliglustat hemitartrate and intermediates thereof
Kanaram Hanumanprasad Kumawat
,
B. R. Patel
,
+8 authors
Ankit Ramjibhai Buha
2018
Corpus ID: 104442814
2017
2017
Type 1 Gaucher disease (CYP2D6-eliglustat).
L. Becquemont
The´rapie (Paris)
2017
Corpus ID: 205359453
2015
2015
Carcinogenicity testing of eliglustat in mice and rats.
R. Dagher
,
M. Watzinger
,
G. Chevalier
,
C. Thirion-Delalande
,
F. Gervais
,
R. Forster
Regulatory toxicology and pharmacology : RTP
2015
Corpus ID: 5694022
2015
2015
Entwicklung von Orphan Drugs
T. Stulnig
Wiener klinisches Magazin
2015
Corpus ID: 6992704
ZusammenfassungErkrankungen, die bei weniger als 5 von 10.000 Einwohnern auftreten, werden in Europa als „seltene Erkrankungen…
Expand
Review
2014
Review
2014
Pedigree analysis in patients with Fabry disease: evaluating changes in referral and diagnosis over successive generations
C. Lavery
,
D. Hughes
,
U. Ramaswami
,
C. Hendriksz
,
T. Hiwot
2014
Corpus ID: 73299127
2014
2014
EDGE: A Phase 3 study evaluating once versus twice daily dosing of eliglustat in patients with Gaucher disease type 1: interim results from the lead-in-period
J. Charrow
,
H. Ida
,
+4 authors
Yong Xue
2014
Corpus ID: 71884108
2013
2013
ENCORE: A randomized, controlled, open-label non-inferiority study comparing eliglustat to imiglucerase in Gaucher disease type 1 patients on enzyme replacement therapy who have reached therapeutic…
T. Cox
,
G. Drelichman
,
+8 authors
A. Puga
2013
Corpus ID: 71784792
2013
2013
Carcinogenicity testing of eliglustat in the mouse and rat
R. Dagher
,
J. Marquis
,
M. Watzinger
,
R. Forster
2013
Corpus ID: 87386841
2012
2012
Eliglustat, an Investigational Oral Therapy for Gaucher Disease Type 1: Phase 2 Results After 4 Years of Treatment
M. J. Peterschmitt
,
E. Lukina
,
+9 authors
A. Puga
2012
Corpus ID: 208347181
Abstract 1038 Introduction: In Gaucher disease type 1 (GD1), genetically caused deficiency of the enzyme acid β-glucosidase…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE